ACCEL Lite: ESC Hot Line: CLEAR Outcomes Total Events Analysis

Results presented at the European Society of Cardiology Congress 2023 further support the long-term use of bempedoic acid in patients at high-risk of cardiovascular events and demonstrate particular benefit in those with diabetes. In this interview, Stephen J. Nicholls MBBS, PhD, FACC and Erin D. Michos, MD, MHS, FACC, discuss the total events analysis from the CLEAR Outcomes trial.

This ACCEL episode is part of an ACC course titled Bempedoic Acid: New Evidence Transforming the LDL-C Treatment Landscape. Educational grant support is provided by Esperion. More content will be available here  soon.

Related References:

  1. Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, Ray KK, Mason D, Kastelein JJP, Cho L, Libby P, Li N, Foody J, Louie MJ, Lincoff AM. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA. 2023 Jul 11;330(2):131-140. doi: 10.1001/jama.2023.9696. PMID: 37354546; PMCID: PMC10336623.
  2. Nicholls S, Lincoff AM, Bays HE, Cho L, Grobbee DE, Kastelein JJ, Libby P, Moriarty PM, Plutzky J, Ray KK, Thompson PD, Sasiela W, Mason D, McCluskey J, Davey D, Wolski K, Nissen SE. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021 May;235:104-112. doi: 10.1016/j.ahj.2020.10.060. Epub 2020 Oct 24. PMID: 33470195.
  3. Krishna Mohan GV, Chenna VSH, Tirumandyam G, Mian AR, Rashid A, Saleem F. Efficacy and Safety of Bempedoic Acid to Prevent Cardiovascular Events in Individuals at Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized-Control Trials. Cureus. 2023 May 7;15(5):e38662. doi: 10.7759/cureus.38662. PMID: 37288183; PMCID: PMC10242672.

Clinical Topics: Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Prevention

Keywords: ACCELLite, Dyslipidemias

< Back to Listings